Abstract:Introduction: Curcumin, the active ingredient of turmeric, generates reactive oxygen species, increases p53 expression, inhibits NFⲕB signaling, and can induce apoptosis. Despite these potential anticancer effects, there has not yet been a systematic analysis of the effects of curcumin on a large panel of cancer cell lines. We hypothesized that curcumin has differential effects based on the specific cell line and its tissue of origin. This study assessed curcumin's anticancer properties via cell survival assays and gene expression analyses. Methods: Cell survival assays were performed by the CTD2 Centre at the Broad Institute. 860 human cancer cell lines were seeded into 1536-well plates, and 24 hours after plating, either DMSO control or curcumin was added to the wells at 16 different concentrations by serial dilution. 72 hours later, cellular ATP levels were measured with CellTiter-Glo as an indication of cell survival. For gene expression analysis, the L1000 assay from the Broad Institute was used. 9 core cell lines were treated with 10 μM of curcumin in 384-well plates. After 6 and 24 hours of incubation, a gene expression signature was identified with the Affymetrix GeneChip HG-U133 Plus 2.0 Array. This signature was compared against signatures from other small molecule and genetic perturbations contained in the CMap database. Afterwards, connectivity scores (incorporating an enrichment score, nominal p-value, and false discovery rate) were used to rank the L1000 signatures by similarity to the signature induced by curcumin. Results: Curcumin was most potent against SEM (IC50 = 1.00 μM; B-acute lymphoblastic leukemia), RPMI-8226 (IC50= 1.62 μM; myeloma), and SCC-4 (IC50 = 1.81 μM; squamous cell carcinoma) cell lines. Lymphoid and peripheral nervous system cancers were generally the most sensitive to curcumin, whereas prostate cancers were the least sensitive. Curcumin-induced gene expression changes resembled GPR87 and PRKRA knockdowns, which are associated with reductions in cancer cell survival, chemoresistance, and proliferation in various cancer cell lines. However, these transcriptomic changes also resembled CERS2 downregulation, which is associated with increased cell migration. In vitro, curcumin treatment mimicked 2',5'-dideoxyadenosine, BMS-299897, and eudesmic acid administration. Conclusion: Curcumin induces changes in cell survival and gene expression that support its anticancer properties in a variety of cancer cell lines. However, separating these effects from CERS2 downregulation may be an important component of future translational research for curcumin and its analogs. Citation Format: Adin Aggarwal, Jacqueline H. Law, Clement Lo, Kenneth W. Yip. A systems biology approach uncovers the anticancer mechanisms of curcumin [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 645.

Exploring the therapeutic potential of curcumin in oral squamous cell carcinoma (HSC-3 cells): Molecular insights into hypoxia-mediated angiogenesis

Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy

The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer

Assessing the Effects of Curcumin and 450 nm Photodynamic Therapy on Oxidative Metabolism and Cell Cycle in Head and Neck Squamous Cell Carcinoma: An In Vitro Study

Curcuminoids Induce Reactive Oxygen Species and Autophagy to Enhance Apoptosis in Human Oral Cancer Cells.

[Anti-Proliferative and Anti-Metastatic Effects of Curcumin on Oral Cancer Cells].

Elucidating the Anticancer Mechanisms of Cinnamoyl Sulfonamide Hydroxamate: Insights From DNA Content Analysis and Gene Expression Profiling in Squamous Cell Carcinoma

Curcumin Nanoemulsions Inhibit Oral Squamous Cell Carcinoma Cell Proliferation by PI3K/Akt/mTOR Suppression and Mir-199A Upregulation: A Preliminary Study.

Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells

Abstract 645: A systems biology approach uncovers the anticancer mechanisms of curcumin

Curcumin Induces G2/M Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma in Vitro and in Vivo Through Atm/Chk2/P53-Dependent Pathway

Curcumin and Related Compounds in Cancer Cells: New Avenues for Old Molecules

Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments

Curcumin as therapeutics for the treatment of head and neck squamous cell carcinoma by activating SIRT1

Effects of Curcumin on Radiation/Chemotherapy-Induced Oral Mucositis: Combined Meta-Analysis, Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

A systems biology investigation of curcumin potency against TGF-β-induced EMT signaling in lung cancer

In vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsions

Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells

Curcumin in cancer therapy: Exploring molecular mechanisms and overcoming clinical challenges

The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway

Curcumin and cancer biology: Focusing regulatory effects in different signalling pathways